0%

Improving Public Health with Innovative Medicines and Caring Expertise

Metabolic Database

SBK harnesses its industry-leading AI-powered metabolic research platform to integrate cutting-edge global R&D breakthroughs. Through multi-dimensional data modeling, it precisely identifies clinical metabolic deficiencies in drug candidates. Centered on an AI-driven drug metabolism analysis and intelligent design system, the platform dynamically collects cross-species metabolic data to build a comprehensive AI-powered metabolic database, enabling end-to-end R&D iteration from early discovery to clinical translation. This approach targets unmet clinical needs and delivers innovative therapies with precision.

R&D Pipeline-Respiratory System

With a focus on the respiratory field, we are dedicated to developing the world’s most advanced, metabolically differentiated therapies. Several products are already in clinical trial stages.

R&D Pipeline-Cardiovascular & Cerebrovascular

With a focus on cardiovascular and cerebrovascular diseases, we are committed to developing the world’s most advanced and differentiated therapies in cardiovascular metabolism. Several products are already in clinical trial stages.

News Center

2025.03.07
On March 6, 2025, Shibeikang Biomedical Technology Co., Ltd. (referred to as “SBK”) achieved a major milestone with the approval of its innovative SBK013 tabl...
2024.12.14
From December 13 to 15, 2024, the Second Annual Conference of the National Key Laboratory for Major Disease Novel Drug Target Discovery and Development took pla...
2024.11.30
Chengdu Shibeikang Biomedical Technology Co., Ltd. (the Company) is excited to announce that its self-developed Chloral Hydrate Syrup has been officially includ...
About Us

Rooted in China, Serving the World, Dedicated to Differentiated Drug Innovation